DK3434762T3 - Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet - Google Patents

Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet Download PDF

Info

Publication number
DK3434762T3
DK3434762T3 DK18194107.1T DK18194107T DK3434762T3 DK 3434762 T3 DK3434762 T3 DK 3434762T3 DK 18194107 T DK18194107 T DK 18194107T DK 3434762 T3 DK3434762 T3 DK 3434762T3
Authority
DK
Denmark
Prior art keywords
natural killer
modified
cell lines
increased cytotoxicity
killer cells
Prior art date
Application number
DK18194107.1T
Other languages
Danish (da)
English (en)
Inventor
Michael Eamon Peter O'dwyer
Original Assignee
Onk Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603655.0A external-priority patent/GB201603655D0/en
Priority claimed from GBGB1610164.4A external-priority patent/GB201610164D0/en
Application filed by Onk Therapeutics Ltd filed Critical Onk Therapeutics Ltd
Application granted granted Critical
Publication of DK3434762T3 publication Critical patent/DK3434762T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK18194107.1T 2015-07-29 2016-07-28 Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet DK3434762T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15178899 2015-07-29
GBGB1603655.0A GB201603655D0 (en) 2016-03-02 2016-03-02 Modified natural killer cells and natural killer cell lines having increased cytotoxicity
GB201605457 2016-03-31
GBGB1610164.4A GB201610164D0 (en) 2016-06-10 2016-06-10 Modified natural killer cells and natural killer cell lines having increased cytoxicity
EP16750677.3A EP3317401B1 (en) 2015-07-29 2016-07-28 Modified natural killer cells and natural killer cell lines having increased cytotoxicity

Publications (1)

Publication Number Publication Date
DK3434762T3 true DK3434762T3 (da) 2021-06-07

Family

ID=56683913

Family Applications (3)

Application Number Title Priority Date Filing Date
DK18194107.1T DK3434762T3 (da) 2015-07-29 2016-07-28 Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK16750677.3T DK3317401T3 (da) 2015-07-29 2016-07-28 Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK18187137.7T DK3421590T3 (da) 2015-07-29 2016-07-28 Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK16750677.3T DK3317401T3 (da) 2015-07-29 2016-07-28 Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK18187137.7T DK3421590T3 (da) 2015-07-29 2016-07-28 Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet

Country Status (13)

Country Link
US (3) US10034925B2 (enExample)
EP (6) EP3971284B1 (enExample)
JP (3) JP6974681B2 (enExample)
KR (1) KR20180028530A (enExample)
CN (3) CN116064400B (enExample)
AU (2) AU2016300128B2 (enExample)
BR (1) BR112018001660A2 (enExample)
CA (2) CA2993796C (enExample)
DK (3) DK3434762T3 (enExample)
ES (5) ES2701338T3 (enExample)
HK (1) HK1252582B (enExample)
MX (2) MX380813B (enExample)
WO (1) WO2017017184A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
EP3971284B1 (en) 2015-07-29 2023-11-08 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US10906951B2 (en) 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
KR20190114966A (ko) 2016-12-09 2019-10-10 온키뮨 리미티드 조작된 자연 살해 세포 및 이의 용도
JP7118072B2 (ja) * 2017-01-06 2022-08-15 イミュニティーバイオ インコーポレイテッド Ｃｄ９６／ｔｉｇｉｔ発現が低下した遺伝子改変型ｎｋ－９２細胞
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
DE102017002645A1 (de) * 2017-03-17 2018-09-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Bestrahlung von Säugetierzellen mit Elektronenstrahlen und/oder Röntgenstrahlen
WO2019016360A1 (en) * 2017-07-21 2019-01-24 Cellectis MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
AU2018303686B2 (en) * 2017-07-21 2025-04-03 Cellectis Engineered immune cells resistant to tumor microoenvironment
WO2019101998A1 (en) 2017-11-24 2019-05-31 Onkimmune Limited Modified natural killer cells and natural killer cell lines targetting tumour cells
WO2019222503A1 (en) * 2018-05-16 2019-11-21 Research Institute At Nationwide Children's Hospital Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins
WO2019232631A1 (en) * 2018-06-06 2019-12-12 Stemcell Technologies Canada Inc. Kits, compositions and methods for myeloid-derived suppressor cell enrichment
CN108743595B (zh) * 2018-06-08 2020-11-27 厦门诺康得生物科技有限公司 一种nk细胞免疫检查点抑制剂及其制备方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN113891934A (zh) 2018-11-21 2022-01-04 因达普塔治疗公司 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
JP2022520402A (ja) * 2019-02-15 2022-03-30 エディタス・メディシン、インコーポレイテッド 免疫療法のための改変ナチュラルキラー（ｎｋ）細胞
CN109908155A (zh) * 2019-03-11 2019-06-21 上海中医药大学 丹参酮ⅱa的药物用途
WO2020189942A1 (ko) * 2019-03-15 2020-09-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
KR102292657B1 (ko) 2019-03-15 2021-08-24 한국과학기술연구원 암 상살 능력이 향상된 면역세포
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2020188105A1 (en) 2019-03-21 2020-09-24 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
CN109970869A (zh) * 2019-04-12 2019-07-05 南京卡提医学科技有限公司 一种靶向人trail死亡受体的嵌合受体配体及其应用
RU2731293C1 (ru) 2019-04-12 2020-09-01 Игорь Петрович Белецкий Способ получения генно-модифицированных линий клеток натуральных киллеров с нокаутированным геном PD-1 и повышенной экспрессией белков семейства Фактора Некроза Опухолей для иммунотерапии онкологических заболеваний
EP3789485A1 (en) 2019-09-06 2021-03-10 ONK Therapeutics Limited Cellular therapies for cancer
EP4038190A1 (en) 2019-10-03 2022-08-10 Artisan Development Labs, Inc. Crispr systems with engineered dual guide nucleic acids
CN111849896B (zh) * 2020-07-31 2022-07-01 广东昭泰体内生物医药科技有限公司 一种car-nk细胞培养基及其应用
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
AU2022227650A1 (en) 2021-02-25 2023-10-12 Celyntra Therapeutics Sa Compositions and methods for targeting, editing, or modifying genes
WO2022256448A2 (en) 2021-06-01 2022-12-08 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
WO2022266538A2 (en) 2021-06-18 2022-12-22 Artisan Development Labs, Inc. Compositions and methods for targeting, editing or modifying human genes
WO2022263682A1 (en) 2021-06-18 2022-12-22 Onk Therapeutics Limited Double knockout natural killer cells
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
CN114544971B (zh) * 2022-02-22 2024-08-30 广东省科学院动物研究所 一种功能蛋白活性的检测方法
WO2023167882A1 (en) 2022-03-01 2023-09-07 Artisan Development Labs, Inc. Composition and methods for transgene insertion
CN114796483B (zh) * 2022-06-28 2022-11-08 北京大学 活化t细胞与阻断性抗体联合制备抗肿瘤药物的用途及抗肿瘤药物
EP4353741A1 (en) 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
JP2025536042A (ja) 2022-11-10 2025-10-30 オーエヌケイ セラピューティクス リミテッド 免疫調節薬を用いた併用療法
CN116590237B (zh) * 2023-05-29 2023-10-31 上海贝斯昂科生物科技有限公司 一种遗传修饰的自然杀伤细胞及其制备和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002751A2 (en) 2000-06-30 2002-01-10 University Of Louisville Research Foundation, Inc. Alteration of cell membrane
CA2388441A1 (en) 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
WO2006004518A1 (en) * 2004-07-02 2006-01-12 Avaris Ab Method for the genetic activation of cells and uses of said cells
US7618817B2 (en) * 2004-07-10 2009-11-17 Fox Chase Cancer Center Genetically modified human natural killer cell lines
EP1621550A1 (en) 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
CN102908612A (zh) * 2011-08-02 2013-02-06 北京诺赛基因组研究中心有限公司 TRAIL截短型变异体活化NF-κB和在炎症反应中的应用
ES2824024T3 (es) * 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
CN103073644B (zh) * 2012-12-31 2014-03-12 中国科学技术大学 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用
CN105593373A (zh) * 2013-02-27 2016-05-18 博德研究所 T细胞平衡基因表达、物质组合物及其使用方法
JP6395323B2 (ja) 2013-07-25 2018-09-26 株式会社ブリヂストン 防振装置
ES2967538T3 (es) * 2013-08-22 2024-04-30 Council Queensland Inst Medical Res Modulación del inmunorreceptor para el tratamiento del cáncer e infecciones virales
KR102357968B1 (ko) * 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
FI3888674T3 (fi) 2014-04-07 2024-07-02 Novartis Ag Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
WO2015161276A2 (en) 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
CA2961636A1 (en) * 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
BR112017020750A2 (pt) 2015-03-27 2018-06-26 Harvard College células t modificadas e métodos de produção e utilização das mesmas
US20180171298A1 (en) * 2015-06-30 2018-06-21 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
JP7146632B2 (ja) * 2015-07-21 2022-10-04 ノバルティス アーゲー 免疫細胞の有効性および増大を改善する方法
EP3971284B1 (en) * 2015-07-29 2023-11-08 ONK Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
WO2019101998A1 (en) * 2017-11-24 2019-05-31 Onkimmune Limited Modified natural killer cells and natural killer cell lines targetting tumour cells
WO2021209625A1 (en) * 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Also Published As

Publication number Publication date
EP3971284A1 (en) 2022-03-23
JP6974681B2 (ja) 2021-12-01
HK1252582A1 (en) 2019-05-31
ES2701338T3 (es) 2019-02-21
ES2970269T3 (es) 2024-05-27
EP3421590B1 (en) 2021-07-14
CA3156128A1 (en) 2017-02-02
CN116064400A (zh) 2023-05-05
RU2018104871A (ru) 2019-08-28
JP2021169473A (ja) 2021-10-28
EP3878951A1 (en) 2021-09-15
MX380813B (es) 2025-03-12
CA2993796A1 (en) 2017-02-02
JP2018522592A (ja) 2018-08-16
CN116064400B (zh) 2025-09-16
AU2022203339A1 (en) 2022-06-09
CN108026512B (zh) 2022-09-16
US10960064B2 (en) 2021-03-30
MX2020010014A (es) 2020-10-14
EP3828266A1 (en) 2021-06-02
ES2939084T3 (es) 2023-04-18
US20170157230A1 (en) 2017-06-08
CA2993796C (en) 2024-02-20
EP3828266B1 (en) 2022-11-23
BR112018001660A2 (pt) 2018-09-18
AU2016300128A1 (en) 2018-02-22
AU2016300128B2 (en) 2022-03-17
DK3317401T3 (da) 2019-01-02
RU2018104871A3 (enExample) 2020-08-17
ES2890859T3 (es) 2022-01-24
US20180326029A1 (en) 2018-11-15
HK1252582B (en) 2020-02-07
EP3421590A1 (en) 2019-01-02
EP3971284B1 (en) 2023-11-08
EP3317401A1 (en) 2018-05-09
WO2017017184A1 (en) 2017-02-02
EP3434762A1 (en) 2019-01-30
ES2876938T3 (es) 2021-11-15
JP2021178824A (ja) 2021-11-18
KR20180028530A (ko) 2018-03-16
CN108026512A (zh) 2018-05-11
US10034925B2 (en) 2018-07-31
CN116064401A (zh) 2023-05-05
MX2018001074A (es) 2018-11-12
DK3421590T3 (da) 2021-10-04
JP7359346B2 (ja) 2023-10-11
US20210138051A1 (en) 2021-05-13
EP3434762B1 (en) 2021-03-17
EP3317401B1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
DK3434762T3 (da) Modificerede, naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
DK3143134T3 (da) Modificerede, naturlige dræberceller og anvendelser deraf
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
IL259586B (en) Genetically modified stem cells and uses thereof
EP3562492A4 (en) GENETICALLY MODIFIED NATURAL KILLER CELLS
DK3581190T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
IL253248A0 (en) Natural killer cells and their uses
IL255011A0 (en) Modified gamma delta cells and uses thereof
IL257105A (en) Modified cells and methods of therapy
IL262359A (en) Ex vivo bite-activated t cells
DK3597742T3 (da) Car-udtrykkende vektor og car-udtrykkende t-celler
PT3191284T (pt) Células e módulos fotovoltaicos encapsulados
DK3138048T3 (da) Kodede celler og cellearrays
EP3325698A4 (en) CELL CULTURE, TRANSPORT AND INVESTIGATION
IL259202A (en) Modified immune cells and uses thereof
DK3586821T3 (da) Stamcellestimulerende sammensætninger og metoder
IL282220B (en) Genetically-engineered drug resistant t cells and methods of using the same
DK3313869T3 (da) Cyklisk rgd-cellebindende motiv og anvendelser deraf
DK3356524T3 (da) Forøget genlevering til naturlige dræberceller, hæmatopoietiske stamceller og makrofager
GB201704953D0 (en) Natural killer cells
DK3226905T3 (da) Hyaluronan-konjugater med farmaceutisk aktive substanser, fremgangsmåder og sammensætninger
DK3118387T3 (da) Solcelletagsten og solcelletagstenssystem
DK3589728T3 (da) Naturlige dræberceller
DK3304240T3 (da) Effektomformer og tilhørende strømnet
IL258193A (en) Modified death-inducing cells with anti-pyotactic properties and their use